Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs

Clin Exp Immunol. 2001 Nov;126(2):274-9. doi: 10.1046/j.1365-2249.2001.01667.x.


Local immune reactivity in the lungs of BALB/c mice was studied following (i) intranasal (i.n.) vaccination with Mycobacterium bovis BCG, (ii) intravenous (i.v.) challenge with a virulent M. bovis field isolate and (iii) i.n. vaccination with M. bovis BCG followed by i.v. challenge with an M. bovis field isolate. The results demonstrated that i.n. vaccination with BCG induced a high degree of protection against systemic M. bovis challenge, and that this protection correlated with a rapid production of IFN-gamma after M. bovis challenge by lung T cells from vaccinated mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Animals
  • BCG Vaccine / administration & dosage*
  • Cytokines / biosynthesis
  • Hypersensitivity, Delayed
  • In Vitro Techniques
  • Interferon-gamma / biosynthesis*
  • Lung / immunology
  • Lymphocyte Activation
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mycobacterium bovis* / immunology
  • Mycobacterium bovis* / pathogenicity
  • T-Lymphocytes / immunology
  • Tuberculosis / immunology
  • Tuberculosis / prevention & control*
  • Virulence


  • BCG Vaccine
  • Cytokines
  • Interferon-gamma